ArticleEJNMMI research2025
Construction of a high-sensitivity Cherenkov luminescence endoscopy system for the detection of gastrointestinal cancers.
Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- NIS-Centered Reporter Gene Imaging and Radionuclide-Integrated Nanoplatforms for Quantitative Tracking of Immune Cell Therapy in Oncology and Inflammatory Disease Models.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Early diagnosis of colorectal cancer using Cerenkov luminescence endoscopy: a pilot trial involving humans for the first time.Theranostics · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundThe diagnostic yield of conventional gastrointestinal (GI) endoscopy for early cancers is low because it is mainly based on morphological changes of tumors. Molecular functional changes in tumors precede morphological changes. Cherenkov luminescence endoscopy (CLE) system can perform molecular imaging of GI cancers, achieving early diagnosis of cancers. However, previous CLE systems had only been able to detect Cherenkov luminescence (CL) from about one μCi nuclide at a minimum (in vivo), but the nuclide probe absorbed by the tumor of a patient was often much less than one μCi at a routinely administered dose. This study aims to construct a clinically usable high-sensitivity CLE for molecular imaging of GI cancers.
resultsThe minimum resolvable radioactivity of the CLE reached 0.020 μCi within 300 s (in vivo), with a sensitivity at the nanocurie for the first time. The detection sensitivity of the CLE increased by up to nearly twenty-two times over the previous system. In tumor-bearing nude mice, CLE could effectively identify all tumors with 100% concordance with both histopathology and PET/CT, and the CL signals of tumors were much stronger than those of the surrounding normal tissues (P < 0.05). The quality of CLE imaging at 60 s was comparable to that at 300 s (signal-to-background ratio, 2.70 ± 0.48 versus 2.98 ± 0.69, P = 0.56).
conclusionsWe constructed a high-sensitivity CLE that could detect radionuclides at the nanocurie radioactivity. The CLE could detect cancers accurately through rapid molecular imaging and had the potential for early diagnosis of GI cancers in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.